Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025.

Curr Oncol · 2026 · PMC12938948 · PMID 41744870

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the phase 3 FALCON study, first-line fulvestrant in patients with HR+/HER2− advanced breast cancer showed a trend for improved OS compared to anastrozole in patients with bone-only disease (median OS 65.2 vs. 47.8 months, respectively; HR 0.85, 95% CI 0.60–1.20) [ 71 ] [ESMO-MCBS v2.0 score: 2].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.